Swiss pharmaceutical giant Novartis (NYSE: NVS) has invested over 600 million Chinese yuan (approximately USD 86.4 million) to establish a new radiotherapy production facility in China.
Located in Haiyan, Zhejiang province—roughly 60 miles from Shanghai—the new plant is slated to become operational by 2026, enhancing Novartis’ capacity for local production.
This initiative complements Novartis’ existing radioligand therapy manufacturing operations in Beijing, which have been in place since 1987. The Beijing facility boasts an impressive production capacity of 3 billion pieces annually, along with the ability to package 400 million boxes each year.- Flcube.com
